Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

Four years af­ter the Eu­ro­pean Com­mis­sion sanc­tioned the use of Cel­gene’s flag­ship Revlim­id to treat adults with pre­vi­ous­ly-un­treat­ed mul­ti­ple myelo­ma who are not el­i­gi­ble for trans­plant, Eng­land’s Na­tion­al Health Ser­vice (NHS) will adopt its use as the first or sec­ond line of de­fense — in cer­tain pa­tients. Al­though the block­buster drug is rou­tine­ly used as a back­bone treat­ment in much of the de­vel­oped world, un­til now, the drug was on­ly cleared for third-line use by NICE.

Revlim­id, which gen­er­at­ed rough­ly $9.7 bil­lion in glob­al 2018 sales, has long been Cel­gene’s key­stone treat­ment, but its use in Eng­land had been re­strained due to pric­ing dis­agree­ments. The drug is al­so cru­cial to Bris­tol-My­er’s $BMY $74 bil­lion bet on the big biotech (al­though the loss of patent pro­tec­tion is loom­ing).

Mul­ti­ple myelo­ma is a life-threat­en­ing form of blood can­cer, which orig­i­nates in the bone mar­row, and af­fects rough­ly 17,500 peo­ple in the UK at any giv­en time, ac­cord­ing to char­i­ty Myelo­ma UK, which es­ti­mates each year that about 5,700 new pa­tients are di­ag­nosed with the dis­ease.

NICE pub­lished two pieces of fi­nal draft guid­ance on Fri­day. In the first re­port, NICE rec­om­mend­ed the use of Revlim­id — known chem­i­cal­ly as lenalido­mide — in com­bi­na­tion with the cor­ti­cos­teroid dex­am­etha­sone as an op­tion for treat­ment-naive adults with mul­ti­ple myelo­ma who are not el­i­gi­ble for a stem cell trans­plant and can­not take thalido­mide. This new op­tion could ben­e­fit about 2,100 pa­tients, NICE said.

Thalido­mide (or borte­zomib, or Take­da’s $TAK Vel­cade, for those who can’t take thalido­mide) re­mains the first line of de­fense, al­though NICE ac­knowl­edged that se­vere side-ef­fects as­so­ci­at­ed with its use can rule out its adop­tion. How­ev­er, “(l)enalido­mide plus dex­am­etha­sone can­not be rec­om­mend­ed for un­treat­ed mul­ti­ple myelo­ma in peo­ple who could take thalido­mide be­cause this would not be cost ef­fec­tive,” NICE un­der­scored.

Lenalido­mide is avail­able as a 21‑cap­sule pack, and its cost varies per dose, up to £4,368 for the high­est 25 mg dose/pack. But, Cel­gene $CELG has now agreed to a (con­fi­den­tial) dis­count that has sat­is­fied NICE. 

In the sec­ond re­port, NICE backed the use of lenalido­mide as an op­tion for treat­ing mul­ti­ple myelo­ma in adults if they have had on­ly one pre­vi­ous ther­a­py, in­clud­ing borte­zomib. Par­tic­u­lar­ly for those that have been first treat­ed with borte­zomib, the on­ly next treat­ment in the doc­tor’s tool­box is chemother­a­py — how­ev­er, ev­i­dence in­di­cates that the lenalido­mide+dex­am­etha­sone is more ef­fec­tive than cy­to­tox­ic chemother­a­py. In one clin­i­cal study, pa­tients tak­ing lenalido­mide lived on av­er­age 7 months longer, NICE said.

About 320 pa­tients are ex­pect­ed to ben­e­fit, it added.

The most ‘plau­si­ble’ cost-ef­fec­tive­ness es­ti­mate for lenalido­mide plus dex­am­etha­sone may be above the range that NICE nor­mal­ly con­sid­ers be­ing a cost-ef­fec­tive use of NHS re­sources, re­searchers high­light­ed in the re­port, but con­ced­ed that since lenalido­mide has been rec­om­mend­ed for use as a first treat­ment (for which it is cost-ef­fec­tive) — the need for lenalido­mide as a sec­ond treat­ment will like­ly de­crease be­cause peo­ple are more like­ly to have it as a first treat­ment in the fu­ture.

Last month, NICE al­so backed the use of J&J’s $JNJ Darza­lex in com­bi­na­tion with Vel­cade as a sec­ond-line treat­ment for mul­ti­ple myelo­ma via the can­cer drugs fund.

Cel­gene, mean­while, is ad­vanc­ing the use of triplet mul­ti­ple myelo­ma ther­a­pies. On Thurs­day, the EU ap­proved 1) Revlim­id in com­bi­na­tion with Vel­cade and dex­am­etha­sone for adult pa­tients with pre­vi­ous­ly un­treat­ed mul­ti­ple myelo­ma who are not el­i­gi­ble for trans­plant; 2) Im­novid in com­bi­na­tion with Vel­cade and dex­am­etha­sone in adult pa­tients with mul­ti­ple myelo­ma, who have re­ceived at least one pri­or treat­ment reg­i­men in­clud­ing Revlim­id.


Im­age Source: As­so­ci­at­ed Press

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci, NIAID director (AP Images)

As new Covid-19 task force gets un­der­way, threat looms of vac­cine, mon­o­clon­al an­ti­body-re­sis­tant vari­ants

Hours before President Biden’s Covid-19 team gave their first virtual press conference, the famed AIDS researcher David Ho delivered concerning news in a new pre-print: SARS-CoV-2 B.1.351, the variant that emerged in South Africa, is “markedly more resistant” to antibodies from convalescent plasma and vaccinated individuals.

The news for several monoclonal antibodies, including Eli Lilly’s bamlanivimab, was even worse: Their ability to neutralize was “completely or markedly abolished,” Ho wrote. Lilly’s antibody cocktail, which was just shown to dramatically reduce the risk of hospitalizations or death, also became far less potent.

Florian Brand (L) and Srinivas Rao (ATAI)

Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

Psychedelics have made a comeback for mental health research, with companies like startup biotech ATAI Life Sciences raising millions and earning the backing of prominent investors like Peter Thiel, but there’s a hole at the heart of the resurgence: Researchers still don’t fully understand how they work.

A new partnership between ATAI and world-renowned Mass General Hospital hopes to change that.

Bomb squad called to As­traZeneca vac­cine plant; Lu­men nabs CARB-X award for low-cost an­tidiar­rheal

A plant located in Wrexham, Wales that is packing the Oxford/AstraZeneca Covid-19 vaccine into vials was surrounded by a bomb squad after officials called police to report a suspicious package.

The alert caused a partial evacuation of the plant, the BBC was among those to report Wednesday. The owner of the plant, British drugmaker Wockhardt UK, said it was cooperating with local authorities and that there were no reports of any injuries.